141 related articles for article (PubMed ID: 2015600)
1. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors.
Tzeng JJ; Barth RF; Orosz CG; James SM
Cancer Res; 1991 May; 51(9):2373-8. PubMed ID: 2015600
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of glioma-reactive cytolytic T lymphocyte precursors by means of limiting dilution analysis.
Tzeng JJ; Barth RF; Orosz CG
J Immunol Methods; 1992 Feb; 146(2):177-84. PubMed ID: 1538141
[TBL] [Abstract][Full Text] [Related]
3. B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity.
Paul DB; Barth RF; Yang W; Shen GH; Kim J; Triozzi PL
Gene Ther; 2000 Jun; 7(12):993-9. PubMed ID: 10871746
[TBL] [Abstract][Full Text] [Related]
4. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
5. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
7. Reactivity of tumor-infiltrating, blood, spleen and lymph node lymphocytes against syngeneic glioma target cells.
Stavrou D; Bilzer T; Anzil AP; Hultén M; Kaldrymidou E
Anticancer Res; 1981; 1(3):125-34. PubMed ID: 7342850
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
[TBL] [Abstract][Full Text] [Related]
9. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
Plautz GE; Touhalisky JE; Shu S
Cell Immunol; 1997 Jun; 178(2):101-7. PubMed ID: 9225000
[TBL] [Abstract][Full Text] [Related]
10. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.
Miescher S; Whiteside TL; Moretta L; von Fliedner V
J Immunol; 1987 Jun; 138(11):4004-11. PubMed ID: 3108380
[TBL] [Abstract][Full Text] [Related]
11. Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination.
Graf MR; Prins RM; Hawkins WT; Merchant RE
Cancer Immunol Immunother; 2002 Jun; 51(4):179-89. PubMed ID: 12012105
[TBL] [Abstract][Full Text] [Related]
12. NKR-P1+ cells localize selectively in Rat 9L gliosarcomas but have reduced cytolytic function.
Chambers WH; Bozik ME; Brissette-Storkus SC; Basse P; Redgate E; Watkins S; Boggs SS
Cancer Res; 1996 Aug; 56(15):3516-25. PubMed ID: 8758920
[TBL] [Abstract][Full Text] [Related]
13. Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats.
Chen JC; Chen Y; Wu JM; Su YH; Tai KF; Tseng SH
Cancer Immunol Immunother; 2006 Jul; 55(7):873-83. PubMed ID: 16133106
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
Kjaergaard J; Tanaka J; Kim JA; Rothchild K; Weinberg A; Shu S
Cancer Res; 2000 Oct; 60(19):5514-21. PubMed ID: 11034096
[TBL] [Abstract][Full Text] [Related]
15. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
16. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model.
Clavreul A; Delhaye M; Jadaud E; Menei P
J Neurooncol; 2006 Aug; 79(1):9-17. PubMed ID: 16575532
[TBL] [Abstract][Full Text] [Related]
17. [Subset analysis of tumor infiltrating lymphocytes and peripheral blood lymphocytes in malignant glioma patients].
Matsuhisa T
No To Shinkei; 1995 May; 47(5):466-73. PubMed ID: 7786623
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
[TBL] [Abstract][Full Text] [Related]
19. Effect of nerve growth factor producing cells on anaplastic glioma and pheochromocytoma clones: involvement of other factors.
Vinores SA; Koestner A
J Neurosci Res; 1981; 6(3):389-401. PubMed ID: 7299847
[TBL] [Abstract][Full Text] [Related]
20. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression.
Prins RM; Scott GP; Merchant RE; Graf MR
Cancer Immunol Immunother; 2002 Jun; 51(4):190-9. PubMed ID: 12012106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
